The design and application of target-focused compound libraries

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 6, 2011, Pages 521-531

  Harris, C John ^a   Hill, Richard D ^b   Sheppard, David W ^b   Slater, Martin J ^c   Stouten, Pieter F W ^d  

^a Lydith   (United Kingdom)

^b BioFocus DPI   (United Kingdom)

^c Cresset BioMolecular Discovery Ltd   (United Kingdom)

^d GALAPAGOS NV   (Belgium)

Author keywords

Biofocus; Galapagos; GPCR; Hit rate; HTS; Ion channel; Kinase; Library design; PPI; Softfocus; Target focus

Indexed keywords

AURORA A KINASE; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; LIGAND GATED ION CHANNEL; PROTEIN KINASE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; MOLECULAR LIBRARY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCREENING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; TARGET FOCUSED COMPOUND LIBRARY;

ANIMALS; DRUG DESIGN; HUMANS; ION CHANNELS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN KINASES; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES;

EID: 79958010723     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/138620711795767802     Document Type: Article

References (34)

1. Hopkins, A. L.; Green, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9(10), 430-431. (Pubitemid 38510559)
2. Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening - an overview. Drug Discov. Today, 1998, 3(4), 160-178. (Pubitemid 128715971)
3. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem., 2010, 53(7), 2719-2740.
4. Lipkin, M. L.; Stevens, A. P.; Livingstone, D. J.; Harris, C. J. How large does a compound screening collection need to be? Combin. Chem. High-Throughput Screen., 2008, 11(6), 482-493. (Pubitemid 351969365)
5. Tan, L.; Loukine, E.; Bajorath, J. Similarity searching using fingerprints of molecular fragments involved in protein-ligand interactions. J. Chem. Inf. Model., 2008, 48(12), 2308-2312.
6. Examples: Feher, M.; Gao, Y.; Baber, J. C.; Shirley, W. A.; Saunders, J. The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies. Bioorg. Med. Chem. Lett., 2008, 16(1), 422-427.
7. Renner, S.; Schneider, G. Scaffold-hopping potential of ligand-based similarity concepts. Chem. Med. Chem., 2006, 1(2), 181-185. (Pubitemid 43700297)
8. Examples: WO 2007/131991 (Galapagos, MAPKAPK5 inhibitors); WO 2004/026877 (Schering Corporation, CDK inhibitors); WO 2006/124874 (Kalypsys Inc., B-Raf inhibitors).
9. http://www.pdb.org/pdb/home/home.do.
10. Fischmann T. O.; Hruza A.; Duca J. S.; Ramanathan L.; Mayhood T.; Windsor W. T.; Le H. V.; Guzi T. J.; Dwyer M. P.; Paruch K.; Doll R. J.; Lees E.; Parry D.; Seghezzi W.; Madison V. Structureguided discovery of cyclin-dependent kinase inhibitors. Biopolymers, 2008, 89(5), 372-379.
11. Qian K.; Wang L.; Cywin C. L.; Farmer B. T. 2nd.; Hickey E.; Homon C.; Jakes S.; Kashem M. A.; Lee G.; Leonard S.; Li J.; Magboo R.; Mao W.; Pack E.; Peng C.; Prokopowicz A. 3rd.; Welzel M.; Wolak J.; Morwick T. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J. Med. Chem., 2009, 52(7), 1814-1827.
12. Pogacic, V.; Bullock, A. N.; Fedorov, O.; Filippakopoulos, P.; Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Research, 2007, 67, 6916-6924. (Pubitemid 47105539)
13. Merckx A.; Echalier A.; Langford K.; Sicard A.; Langsley G.; Joore J.; Doerig C.; Noble M.; Endicott J. Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. Structure, 2008, 16(2), 228-238. (Pubitemid 351222652)
14. Simard J. R.; Grütter C.; Pawar V.; Aust B.; Wolf A.; Rabiller M.; Wulfert S.; Robubi A.; Klüter S.; Ottmann C.; Rauh D. Highthroughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. J. Am. Chem. Soc., 2009, 131(51), 18478-18488.
15. For example GLPG0259 in Phase II: http://www.glpg.com/press/2010/30.htm;
16. http://www.glpg.com/pharmaceuticals/ra.htm.
17. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol, 2006, 2, 358-364. (Pubitemid 43936934)
18. Ghose, A. K.: Herbertz, T.; Pippin, D. A.; Salvino, J. M.; Mallamo, J. P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J. Med. Chem., 2008, 51(17), 5149-5171.
19. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged Structures: Applications in Drug Discovery. Combin. Chem. High-Throughput Screen., 2004, 7(5), 473-494.
20. Okram, B.; Nagle, A.; Adrian, F. J.; Lee, C.; Ren, P.; Wang, X.; Sim, T.; Xie, Y.; Wang, X.; Xia, G.; Spraggon, G.; Warmuth, M.; Liu, Y.; Gray, N. S. A general strategy for creating "inactiveconformation" Abl inhibitors. Chem. Biol, 2006, 13(7), 779-786. (Pubitemid 44109805)
21. Doyle, D. A.; Cabral, J. M,; Pfuetzner, R. A.; Kuo, A,.; Gulbis, J. M.; Cohen, S. L.; Chalt, B. T.; Mackinnon, R. The structure of the potassium channel: Molecular basis of K+ conduction and selectivity. Science, 1998, 280, 69-77. (Pubitemid 28169082)
22. http://www.cresset-bmd.com/product/fieldtemplater.
23. Yamamoto, T.; Nagabukuro, M.; Manabu, H. M. Preparation of phenylurea derivatives as vanilloid receptor agonists, WO 2003/029199.
24. ": A chemogenomic approach to GPCR drug discovery. Cur. Top Med. Chem., 2011, in the press.
25. Parthier, C.; Reedtz-Runge, S.; Rudolph, R.; Stubbs, M. T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci., 2009, 34(6), 303-310.
26. Crossley, R.; Slater, M. J. A reductionist approach to chemogenomics in the design of drug molecules and focused libraries. In Chemogenomics (Ed. Jacoby, E.), Imperial College London Press, 2006, pp. 85-108.
27. Souers, A. J.; Virgilio, A. A.; Schurer, S. S.; Ellman, J. A.; Kogan, T. P.; West, H. E.; Ankener, W.; Vanderslice, P. Novel inhibitors of α4β1 integrin receptor interactions through library synthesis and screening. Bioorg Med. Chem. Lett., 1998, 8(17), 2297-2302. (Pubitemid 28551486)
28. Zinzalla, G.; Thurston, D. E. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med. Chem., 2009, 1(1), 65-93.
29. Robinson, J. A.; DeMarco, S.; Gombert, F.; Moehle, K.; Obrecht, D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov. Today, 2008, 13 (21-22), 944-951.
30. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains. Nature, 2010, 468(7327), 1067-1073.
31. Rodriguez, J. M.; Nevola, L.; Ross, N. T.; Lee, G.; Hamilton, A. D.; Synthetic inhibitors of extended helix-protein interactions based on a biphenyl 4, 4'-dicarboxamide scaffold. ChemBioChem, 2009, 10(5), 829-833.
32. Jacoby, E. Biphenyls as potential mimetics of protein a-helix. Bioorg. Med. Chem. Lett., 2002, 12(6), 891-893. (Pubitemid 34214968)
33. Qiao, J. X.; Cheney, D. L.; Alexander, R. S.; Smallwood, A. M.; King, S. R.; He, K.; Rendina, A. R.; Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Lam, P. Y. S. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of orthosubstituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa. Bioorg Med. Chem. Lett., 2008, 18(14), 4118-4123.
34. Gill, S.; Gill, R.; Wicks, D.; Liang, D. A cell-based Rb (+)-flux assay of the Kv1.3 potassium channel. Assay Drug Dev. Technol, 2007, 5(3), 373-380. (Pubitemid 47067882)